Compare AGNC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGNC | GH |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | 54 | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 12.7B |
| IPO Year | N/A | 2018 |
| Metric | AGNC | GH |
|---|---|---|
| Price | $10.17 | $126.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 19 |
| Target Price | $11.03 | ★ $119.79 |
| AVG Volume (30 Days) | ★ 13.2M | 2.2M |
| Earning Date | 04-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 13.13% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $0.33 | $33.30 |
| Revenue Next Year | $1.16 | $28.27 |
| P/E Ratio | $7.69 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $9.08 | $40.36 |
| 52 Week High | $12.19 | $134.28 |
| Indicator | AGNC | GH |
|---|---|---|
| Relative Strength Index (RSI) | 40.35 | 63.89 |
| Support Level | $10.05 | $94.02 |
| Resistance Level | $10.32 | N/A |
| Average True Range (ATR) | 0.17 | 7.02 |
| MACD | -0.02 | 0.88 |
| Stochastic Oscillator | 18.69 | 78.41 |
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage, or real estate markets.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.